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Abstract
Introduction: Strongyloides stercoralis infection affects hundreds of millions of people worldwide.
As immigration rates and international travel increase, so does the number of cases of
strongyloidiasis in the United States. Although described both in immigrant and in
immunosuppressed populations, hyperinfection and dissemination of S. stercoralis following the
initiation of antiparasitic medication is a previously unreported phenomenon.
Case presentation: Here we describe the case of a 38-year-old immunocompromised woman
with systemic lupus erythematosus, who developed disseminated disease following treatment with
albendazole (400 mg every 12 hours). Notably the patient was receiving oral prednisone (10 mg
once daily), azathioprine (50 mg twice daily), and hydroxychloroquine (400 mg daily) at the time of
hospitalization. The patient was subsequently treated successfully with ivermectin (200 mcg/kg
daily).
Conclusion: The reader should be aware that dissemination of S. stercoralis can occur even after
the initiation of antiparasitic medication.
Introduction
Strongyloides stercoralis is a nematode that infects approxi-
mately 100 million humans worldwide each year. Infec-
tion is endemic in tropical regions and may occur
throughout South America, the Caribbean, Africa, and
Europe [1] as well as the southern United States [2]. As
international travel and immigration rates rise, so does
the number of cases of strongyloidiasis within the United
States. In fact, S. stercoralis can persist for many years with-
out any apparent symptoms in individuals who have vis-
ited an endemic area [3]. Currently, the prevalence of S.
stercoralis carriage in certain Northern American states has
been reported to be as high as 3% of the population [2].
The life cycle of S. stercoralis in humans begins when free-
living infective filariform larvae penetrate the skin and
migrate hematogenously to the lungs [4]. Once the larvae
reach lung capillary beds, they migrate through the capil-
lary walls into the alveolar air spaces. The larvae are
coughed up to the larynx, where they are swallowed, and
thus gain access to the duodenum and jejunum. The lar-
vae develop into adult females, which lay eggs that hatch
non-migratory (rhabditiform) larvae that penetrate the
mucosa, leading to internal auto-infection.
This auto-infective cycle may persist and dissemination
has been reported due to immunocompromised status
from HIV, chemotherapy, or corticosteroid therapy [5-7].
Corticosteroids are widely used in the management of sys-
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temic lupus erythematosus (SLE), and disseminated
strongyloidiasis is reported after corticosteroid adminis-
tration for this disease [8]. Dissemination may involve
gut, stomach, lung and/or cerebrospinal fluid [9,10]. Fur-
thermore, larval penetration of the intestinal wall during
dissemination may result in bacteremia due to the intro-
duction of bowel flora.
It is generally accepted that, without prompt treatment,
hyperinfection may prove fatal. Here we describe the case
of a patient who developed disseminated disease after cor-
ticosteroid treatment for SLE despite treatment with
albendazole. The patient only showed improvement after
institution of ivermectin.
Case presentation
A 38-year-old woman emigrated from the Dominican
Republic 1 year prior to presentation with complaints of 6
days of abdominal pain and blood-flecked emesis. Of
note she had recently been diagnosed with SLE, and was
undergoing treatment with oral prednisone (10 mg once
daily), azathioprine (50 mg twice daily), and hydroxy-
chloroquine (400 mg daily).
Physical examination revealed a thin woman with cushin-
goid features in no acute distress. Vital signs demonstrated
a normothermic, normotensive patient with mild tachy-
cardia. Abdominal examination was notable for epigastric
tenderness and guaiac positive stool. Her skin was noted
to have a diffuse erythematous reticular rash extending
from her abdomen to her upper legs. Laboratory findings
demonstrated mild thrombocytopenia (120,000 plate-
lets/mm3), a white blood cell count of 13,000/mm3, with
an automatic differential of 79.5% neutrophils and 1.1%
eosinophils. Chest X-ray was within normal limits with-
out pulmonary infiltrates. Her urine culture subsequently
grew Klebsiella pneumoniae, and she was treated with cipro-
floxacin. Both azathioprine and celecoxib were discontin-
ued at time of admission.
The patient underwent upper endoscopy that revealed
mild esophagitis and duodenitis. Esophageal brushings
(Figure 1) and a duodenal biopsy (Figure 2) were col-
lected which demonstrated S. stercoralis. Serial stool sam-
ples were collected and were subsequently noted to
contain S. stercoralis. Serology testing by enzyme-linked
immunoassay further confirmed the diagnosis.
Treatment with oral albendazole (400 mg twice daily) was
initiated within 20 hours of presentation; however, the
patient continued to experience abdominal discomfort.
The truncal reticular rash also persisted despite therapy.
Four days after admission, and 3 days after initiation of
albendazole therapy, the patient developed respiratory
distress, high fever, and hypotension. New pulmonary
rales were audible over both lung fields and a chest radio-
graph demonstrated new diffuse opacities. Blood cultures
and urine cultures were obtained. The patient was trans-
ferred to the intensive care unit where she was resuscitated
with intravenous fluids, and received stress dose steroids.
Her antibiotic coverage was broadened to include cipro-
floxacin, metronidazole, vancomycin, and gentamicin,
and her antiparasitic medication was changed to ivermec-
tin (200 mcg/kg once daily). Blood cultures were positive
for  Klebsiella pneumoniae,  Enterococcus faecalis, and
Escherichia coli.
After 10 days of ivermectin and consistently negative stool
examination for ova and parasites, antiparasitic therapy
was discontinued. The patient was continued on appropri-
ate antibiotics for 14 days and discharged home after a total
Duodenal biopsy Figure 2
Duodenal biopsy. Multiple larval forms of Strongyloides ster-
coralis in situ.
Esophageal brushing revealing the larval form of Strongyloides  stercoralis Figure 1
Esophageal brushing revealing the larval form of 
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of 22 days of hospitalization. The patient's serology tests
had returned to normal by her 4-month follow-up visit.
Discussion
Typically, hyperinfection syndrome occurs in patients
from endemic areas of S. stercoralis who receive immuno-
suppressive therapy and present with polymicrobial sep-
sis. The diagnosis in such patients may at times be difficult
because of a lower incidence of eosinophilia. Diagnosis
by a single stool sample may fail to yield a diagnosis, since
the detection rate is cited as 25% [11]. In our patient,
100% of stool samples were positive prior to therapy and
during treatment with albendazole, possibly because of a
high parasitic burden. Infection may also be diagnosed by
serology, and can be followed-up to confirm successful
treatment. Typically, serology will be negative within 6
months of S. stercoralis eradication. Our patient had nor-
mal serology 4 months after completion of therapy.
This case is unusual because disseminated disease
occurred 3 days after initiation of therapy with albenda-
zole. We are uncertain why dissemination occurred in this
time sequence. A possible explanation includes albenda-
zole-resistant S. stercoralis. Data suggest that regional dif-
ferences already exist in albendazole susceptibility in a
variety of nematodes [12]. Albendazole has a tendency to
produce less tolerable side-effect profiles than ivermectin.
Poor tolerance of albendazole by our patient may have led
to malabsorption of albendazole (but not ivermectin).
Randomized trials comparing ivermectin with albenda-
zole and other antihelminths found ivermectin to be suc-
cessful in eradicating larval forms [13]. Other possible
explanations include a delayed response to therapy or
induction of an inflammatory response that resulted in
tissue damage and dissemination. Ivermectin may be
superior to albendazole because of a cidal action on both
the larval and adult forms of S. stercoralis [14,15].
The higher rate of hyperinfection in immunosuppressed
patients receiving corticosteroids is not well understood.
In addition to the broad immunosuppressive effect of cor-
ticosteroids, it has been observed in an animal model of
strongyloides that female worms produce more eggs in
the presence of exogenous steroids. This may further facil-
itate worm growth and development [16].
Conclusion
Clinicians should be aware that the S. stercoralis hyperin-
fection syndrome may occur several days into appropriate
antihelminth therapy and should remain vigilant for signs
of sepsis even during the early days of therapy. Our find-
ings are based on a single case report, and to better com-
pare the utility of albendazole and ivermectin in the
treatment of S. stercoralis hyperinfection syndrome, a ran-
domized prospective trial would be required.
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